CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events

Item 8.01.Other Events.

On December 5, 2016, CytomX Therapeutics, Inc. issued a press
release announcing that Bristol-Myers Squibb selected the fourth
target under the Collaboration and License Agreement between them
(the Agreement) and triggered a $15 million selection payment in
accordance with the Agreement. This constitutes the final target
selection under the Agreement. The full text of the press release
is furnished as Exhibit 99.1 hereto.

Reference is made to the Exhibit Index attached hereto

About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Recent Trading Information

CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) closed its last trading session up +0.79 at 11.00 with 144,200 shares trading hands.